Welcome to Genelux Corporation
“Transforming cancer from a terminal disease to a manageable condition.”
Genelux Corporation is a privately-held biomedical company whose mission is to develop safe and
effective diagnostic and therapeutic solutions for cancer and inflammatory diseases for which there
is no effective treatment today.
The flagship Genelux technology utilizes an attenuated live virus to diagnose and treat cancer without
harming healthy cells in the body. The first Genelux product candidate, GL-ONC1, will enter Phase I
and Phase I/II human trials in the United States and abroad in the near future.